Centre for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases--INDIRA and Department of Internal Medicine II (Hematology, Oncology, Immunology, Rheumatology, Pulmology), University Hospital, Otfried-Mueller-Str. 10, 72076 Tuebingen, Germany.
Clin Rheumatol. 2013 May;32(5):673-8. doi: 10.1007/s10067-012-2155-5. Epub 2013 Jan 10.
The purpose of this study was to assess the impact of enteric-coated mycophenolate sodium (EC-MPS) on skin and pulmonary manifestations of patients with progressive systemic sclerosis (Ssc). A prospective, open-label single-centre trial with EC-MPS 2 × 720 mg/day over 12 months and a long-term follow-up of 50 months were conducted. Modified Rodnan skin score (mRSS) was used to assess the skin and pulmonary function tests to assess the pulmonary involvement. In order to quantify the extent of alveolitis/fibrosis via densitometry, the high attenuation value, median lung density and percentiles of lung tissue densities were obtained by high-resolution computed tomography. Eleven patients were included. Three patients had to stop medication before month 6 (2× side effects, 1× progression). For the remaining eight patients, the median mRSS was non-significantly reduced from 13.5 at baseline to 11 at month 12. According to the CT histography, median lung density and high attenuation values remained stable. However, the course of percentiles -200 to -300 and particularly -300 to -400 Hounsfield units slightly increased in seven of eight patients after 12 months, suggesting worsening of pulmonary involvement. Accordingly, median diffusing capacity for carbon monoxide showed a tendency to decline (75.1 % vs. 70.2) while forced vital capacity non-significantly improved (78.0 vs. 85.5 %) during the study. Four patients are still on EC-MPS without clinical signs of progression after 50 months follow-up. EC-MPS showed non-significant improvement of the skin. Pulmonary fibrosis remained stable with only a slight tendency towards progression which might be ascribed to the medication as well as the natural course of the disease. CT histography appears to be a sensitive method for the detection of progression of pulmonary fibrosis and therefore should be considered for further studies in Ssc.
这项研究的目的是评估肠溶性吗替麦考酚酯钠(EC-MPS)对进行性系统性硬化症(SSc)患者皮肤和肺部表现的影响。进行了一项为期 12 个月、2×720mg/天 EC-MPS 治疗的前瞻性、开放性、单中心试验,并进行了长达 50 个月的长期随访。采用改良 Rodnan 皮肤评分(mRSS)评估皮肤,采用肺功能试验评估肺部受累情况。为了通过密度测定法定量评估间质性肺炎/纤维化的程度,通过高分辨率计算机断层扫描获得高衰减值、肺中位数密度和肺组织密度的百分位数。共纳入 11 例患者。3 例患者在第 6 个月前(2×副作用,1×进展)停止用药。对于其余 8 例患者,mRSS 中位数从基线时的 13.5 分降至 12 分,但无显著差异。根据 CT 组织学,肺中位数密度和高衰减值保持稳定。然而,在 12 个月后,7 例患者中从-200 到-300 、特别是从-300 到-400 个 Hounsfield 单位的百分位数略有增加,提示肺部受累加重。因此,在研究期间,一氧化碳弥散量中位数呈下降趋势(75.1%对 70.2%),而用力肺活量非显著改善(78.0%对 85.5%)。4 例患者在 50 个月的随访后仍在服用 EC-MPS,且无疾病进展的临床迹象。EC-MPS 显示皮肤有非显著改善。肺部纤维化保持稳定,仅略有进展趋势,这可能归因于药物和疾病的自然病程。CT 组织学似乎是检测肺部纤维化进展的敏感方法,因此应考虑在 SSc 中进一步研究。